Screener
Ligand Pharmaceuticals LGND Others — Financial Royalty Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
| Others | 5,729 | (212) | 5,517 | 5,769 | (214) | 5,555 |
| Total financial royalty assets, net | $209,699 | $(2,489) | $207,210 | $222,375 | $(2,706) | $219,669 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's others — financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported others — financial royalty assets, net of $5.52M in Q2 2026.
- What does others — financial royalty assets, net mean?
- This metric represents the net book value of royalty-based intangible assets within the 'Others' segment, calculated as the gross carrying value minus any applicable valuation allowances. It provides a current, risk-adjusted snapshot of the economic value the company expects to derive from these specific pharmaceutical partnerships and licensing arrangements. Investors use this figure to assess the tangible value of the segment's portfolio and its potential to contribute to future royalty revenue.
Ask your AI about Ligand Pharmaceuticals's others — financial royalty assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude